Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Praxadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Praxadine SCHEMBL3579034 | 1.00 | NOS1 (0.95) | — | |
| Praxadine SCHEMBL94070 | 0.98 | — | — | |
| Praxadine SCHEMBL3086435 | 0.95 | — | — | |
| Praxadine SCHEMBL28203296 | 0.95 | — | — | |
| Praxadine SCHEMBL5396070 | 0.84 | NOS1 (0.74) | — | |
| Praxadine SCHEMBL8132131 | 0.82 | NOS1 (0.71) | — | |
| Praxadine SCHEMBL31705643 | 0.82 | — | — | |
| Praxadine SCHEMBL2301207 | 0.80 | NOS1 (0.67) | — | |
| SCHEMBL14936408 | 0.77 | NOS1 (0.65) | — | |
| Hydrochloric Acid SCHEMBL2378439 | 0.77 | NOS1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2298 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346581-A1 | PROCESS FOR SYNTHESIS OF GALBULIMIMA ALKALOID 18 AND COMPOUNDS USEFUL AS OPIOID RECEPTOR ANTAGONISTS AND AGONISTS | SCRIPPS RESEARCH INST (US) | 2025-11-13 | — | — | US | claimed |
| CN-119950742-A | Thiol-nucleic acid aptamer and self-assembled nanomaterial of derivative thereof, and application of thiol-nucleic acid aptamer and self-assembled nanomaterial of derivative thereof in improving stability of nucleic acid aptamer and derivative thereof | 上海纳米技术及应用国家工程研究中心有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119859259-A | Polyamino acid and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2025-04-22 | — | — | CN | claimed |
| CN-119734496-A | Antibacterial composite non-woven fabric | 广州三立无纺布有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-114609306-B | Antibody-independent ubiquitination modification enrichment method and detection method | 中国科学院广州生物医药与健康研究院 | 2025-03-21 | — | — | CN | claimed |
| CN-119409980-A | Preparation method of liquid metal nitric oxide nano-reactor and application of liquid metal nitric oxide nano-reactor in preparation of cancer treatment medicines | 无锡市人民医院 | 2025-02-11 | — | — | CN | claimed |
| CN-117358321-B | Chromatography medium and preparation method thereof | 赛普(杭州)过滤科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117462676-A | Novel root canal flushing system based on photodynamic/NO combination therapy and construction method thereof | 温州医科大学附属口腔医院 | 2024-01-30 | — | — | CN | claimed |
| CN-117358321-A | Chromatography medium and preparation method thereof | 赛普(杭州)过滤科技有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-117286713-A | Antibacterial flame-retardant textile auxiliary, and preparation method and application thereof | 江苏悦孚油品有限公司 | 2023-12-26 | — | — | CN | claimed |
| US-6486174-B2 | TREATMENT OF TUMOR GROWTH, METASTASIS, RESTENOSIS, OSTEOPOROSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, RHEUMATOID ARTHRITIS, SICKLE CELL ANEMIA, NERVE SYSTEM DISORDERS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-26 | — | — | US | claimed |
| US-20020061885-A1 | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-05-23 | — | — | US | claimed |
| WO-2002012193-A1 | TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID ALKOXYGUANIDINES AS INTEGRIN ANTAGONISTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| US-6344484-B1 | TREATMENT OF TUMOR GROWTH, METASTASIS, OSTEOPOROSIS, RESTENOSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, AND RHEUMATOID ARTHRITIS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-05 | — | — | US | claimed |
| EP-1159262-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000047552-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |
| EP-0882014-A1 | PROCESS FOR THE PREPARATION OF N?G -MONOMETHYL-L-ARGININE HYDROCHLORIDE | GLAXO GROUP LIMITED (GB) | 1998-12-09 | — | — | EP | claimed |
| WO-1997030972-A1 | PROCESS FOR THE PREPARATION OF NG-MONOMETHYL-L-ARGININE HYDROCHLORIDE | GLAXO GROUP LIMITED (GB) | 1997-08-28 | — | — | WO | claimed |
| EP-0743320-A2 | Acyl guanidine and amidine prodrugs | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-11-20 | — | — | EP | claimed |
| US-5453514-A | Diabetes | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1995-09-26 | — | — | US | claimed |